ArticleResearch and reports in urology2026

Clinical Outcomes of Sequential Cabozantinib and Axitinib After First-Line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Single-Center Exploratory Study.

Nobuki Furubayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.